MAIA Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
MAIA Biotechnology, Inc. (MAIA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 4.22 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-10
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 3.58M shares, a 145.95% increase year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 641.09K shares, a 43.54% decline year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 949.68K shares, a 56.62% increase year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 478.15K shares, a 470.24% increase year-over-year.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 4.02M shares, a 32.06% increase from fiscal 2024.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 3.04M shares, a 89.41% increase from fiscal 2023.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.61M shares, a 97.95% increase from fiscal 2022.
- MAIA Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 811.83K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.58M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 4.22M shares 10-Q · filed 2026-08-10 | 5.17M shares derived: sum of 3 quarters · filed 2026-08-10 | 5.65M shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 641.09K shares 10-Q · filed 2026-05-11 | 1.59M shares derived: sum of 2 quarters · filed 2026-05-11 | 2.07M shares derived: sum of 3 quarters · filed 2026-05-11 | 3.53M shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2025-12-31 | 949.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | 1.43M shares derived: sum of 2 quarters · filed 2026-03-23 | 2.88M shares derived: sum of 3 quarters · filed 2026-03-23 | 4.02M shares 10-K · filed 2026-03-23 |
| 2025-09-30 | 478.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 1.93M shares derived: sum of 2 quarters · filed 2025-11-07 | 3.07M shares 10-Q · filed 2025-11-07 | 3.68M shares derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-06-30 | 1.46M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 2.59M shares 10-Q · filed 2025-08-11 | 3.20M shares derived: sum of 3 quarters · filed 2025-08-11 | 3.28M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 1.14M shares 10-Q · filed 2025-05-09 | 1.74M shares derived: sum of 2 quarters · filed 2025-05-09 | 1.83M shares derived: sum of 3 quarters · filed 2025-05-09 | 3.19M shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | 606.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | 690.21K shares derived: sum of 2 quarters · filed 2025-03-21 | 2.06M shares derived: sum of 3 quarters · filed 2025-03-21 | 3.04M shares 10-K · filed 2025-03-21 |
| 2024-09-30 | 83.85K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 1.45M shares derived: sum of 2 quarters · filed 2024-11-12 | 2.44M shares 10-Q · filed 2024-11-12 | 2.65M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 1.37M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | 2.35M shares 10-Q · filed 2024-08-09 | 2.56M shares derived: sum of 3 quarters · filed 2024-08-09 | 2.68M shares derived: sum of 4 quarters · filed 2024-08-09 |
| 2024-03-31 | 984.46K shares 10-Q · filed 2024-05-14 | 1.19M shares derived: sum of 2 quarters · filed 2024-05-14 | 1.31M shares derived: sum of 3 quarters · filed 2024-05-14 | 1.92M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 208.15K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 325.52K shares derived: sum of 2 quarters · filed 2024-03-21 | 934.74K shares derived: sum of 3 quarters · filed 2024-03-21 | 1.61M shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 117.37K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 726.59K shares derived: sum of 2 quarters · filed 2023-11-07 | 1.40M shares 10-Q · filed 2023-11-07 | 1.44M shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 609.22K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 1.28M shares 10-Q · filed 2023-08-08 | 1.33M shares derived: sum of 3 quarters · filed 2023-08-08 | 1.92M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 672.29K shares 10-Q · filed 2023-05-08 | 716.00K shares derived: sum of 2 quarters · filed 2023-05-08 | 1.31M shares derived: sum of 3 quarters · filed 2023-05-08 | |
| 2022-12-31 | 43.72K shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-24 | 638.11K shares derived: sum of 2 quarters · filed 2023-03-24 | 811.83K shares 10-K · filed 2023-03-24 | |
| 2022-09-30 | 594.39K shares derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-02-06 | 768.11K shares 10-Q/A · filed 2023-02-06 | ||
| 2022-06-30 | 173.73K shares 10-Q · filed 2022-08-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |